Chongqing Pharscin Pharmaceutical Co.,Ltd.(002907),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

002907 Chongqing Pharscin Pharmaceutical Co.,Ltd.

Closed 01-22 15:00:00

15.26

+0.11

+0.73%

High15.50	Low15.15	Vol2.73M
Open15.18	D1 Closing15.15	Amplitude2.31%
Mkt Cap6.38B	Tradable Cap4.58B	Total Shares418.00M
T/O41.78M	T/O Rate0.91%	Tradable Shares300.00M
P/B3.75	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"Chongqing Pharscin Pharmaceutical Co.,Ltd.","latestPrice":15.26,"timestamp":1769065419000,"preClose":15.15,"halted":0,"volume":2732900,"delay":0,"changeRate":0.0073,"floatShares":300000000,"shares":418000000,"eps":0.1787,"marketStatus":"Closed","change":0.11,"latestTime":"01-22 15:00:00","open":15.18,"high":15.5,"low":15.15,"amount":41777300,"amplitude":0.0231,"askPrice":15.27,"askSize":292,"bidPrice":15.26,"bidSize":139,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769131800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.15,"symbolType":"stock","openAndCloseTimeList":[[1769045400000,1769052600000],[1769058000000,1769065200000]],"highLimit":16.67,"lowLimit":13.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"isCdr":false,"pbRate":3.75,"roa":"--","peRate":85.394516,"roe":"4.31%","epsLYR":0.1837,"committee":-0.103125,"marketValue":6373000000,"turnoverRate":0.0091,"status":0,"floatMarketCap":4577000000},"requestUrl":"/m/hq/s/002907/wiki","defaultTab":"wiki","newsList":[{"id":"2603670634","title":"Pharscin Pharma Gets Nod to Re-Register Eight Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2603670634","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603670634?lang=en_us&edition=fundamental","pubTime":"2026-01-15 16:56","pubTimestamp":1768467405,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  received approval from the Chongqing Municipal Medical Products Administration for the re-registration of eight products, according to a Shenzhen bourse filing on Thursday.The approvals are for pefloxacin mesylate for injection for 0.2 grams and 0.4 grams, citicoline sodium for injection, aciclovir for injection, cilostazol capsules, bumetanide for injection, calcium folinate for injection for 25 milligrams and 100 milligrams.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2593425734","title":"Chongqing Pharscin Pharmaceutical Gets Re-approval for Proton Pump Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2593425734","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593425734?lang=en_us&edition=fundamental","pubTime":"2025-12-24 12:12","pubTimestamp":1766549572,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  obtained re-registration approval from the Chongqing drug administrator for its omeprazole sodium injection.The proton pump inhibitor treats conditions such as peptic ulcer bleeding and reflux esophagitis, according to a Wednesday filing with the Shenzhen bourse.The approval is valid until January 2031.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2585219651","title":"Pharscin Pharmaceutical Completes Drug Filing Application for Rasagiline Mesylate Tablets; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585219651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585219651?lang=en_us&edition=fundamental","pubTime":"2025-11-21 12:48","pubTimestamp":1763700536,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  completed the domestic production drug filing application for rasagiline mesylate tablets with China's National Medical Products Administration, according to a Shenzhen bourse disclosure on Friday.The application enlarges the font size of the drug's filing covers or paper inserts, as well as introduce an electronic version of it, for the aging population to be able to better read and understand the drug's information.The drug is used to treat patients with Parkinson's disease.The pharmaceutical company's shares fell less than 3% during the midday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"1151772571","title":"Chongqing Pharscin Pharmaceutical (002907.SZ) Completes Domestic Production Filing for Rasagiline Mesylate Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1151772571","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151772571?lang=en_us&edition=fundamental","pubTime":"2025-11-20 17:12","pubTimestamp":1763629934,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) announced that it recently learned from the National Medical Products Administration (NMPA) website that its product Rasagiline Mesylate...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2584999907","title":"Pharscin Pharmaceutical Renews Manufacturing License","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999907","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584999907?lang=en_us&edition=fundamental","pubTime":"2025-11-19 11:20","pubTimestamp":1763522410,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  renewed its drug manufacturing license and received a renewed license from the Chongqing Medical Products Administration, according to a Shenzhen bourse filing on Wednesday.The amendment included the extension of Youhua Pharmaceutical Technology's commissioned manufacturing period of montelukast sodium granules to March 2, 2026.The drug is used for the prevention and treatment of asthma in children 1 years old and older, as well as treating allergic rhinitis in children aged 2 to 5 years old.The renewed license is valid until June 29, 2030.The Chinese pharmaceutical company's shares slipped over 1% during the morning trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2583556665","title":"Pharscin Pharmaceutical's Liquid Food Formula for Digestive Disorders Gets China Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556665","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583556665?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:16","pubTimestamp":1763018173,"startTime":"0","endTime":"0","summary":"China's market regulator granted Chongqing Pharscin Pharmaceutical  registration approval for its liquid formula food for individuals with restricted food intake, according to a Thursday filing with the Shenzhen bourse.The formula is indicated for individuals aged 10 and above with restricted fat intake or those experiencing digestive and absorption disorders, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"1105068906","title":"Chongqing Pharscin Pharmaceutical (002907.SZ) Obtains Registration Certificate for Special Medical Use Formula Food","url":"https://stock-news.laohu8.com/highlight/detail?id=1105068906","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105068906?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:20","pubTimestamp":1762939217,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) announced that it recently received the \"Registration Certificate for Special Medical Use Formula Food\" issued by the State Administration for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002907","BK0239"],"gpt_icon":0},{"id":"1143515201","title":"Chongqing Pharscin Pharmaceutical (002907.SZ) Reports Q3 Results: Net Profit Attributable to Shareholders Drops 2.84% YoY to RMB 72.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1143515201","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143515201?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:20","pubTimestamp":1761646855,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical (002907.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of RMB 626 million, representing a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2577840940","title":"Pharscin Pharmaceutical Gets Approval Generic Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2577840940","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577840940?lang=en_us&edition=fundamental","pubTime":"2025-10-21 17:04","pubTimestamp":1761037453,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  obtained drug registration from China's medical products administrator for its crizotinib capsules.The drug is indicated for the treatment of ALK- or ROS1-positive advanced non-small cell lung cancer.Shares of the pharmaceutical company closed 2% higher Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"1111974886","title":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) Obtains Drug Registration Certificate for Crizotinib Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=1111974886","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111974886?lang=en_us&edition=fundamental","pubTime":"2025-10-20 17:44","pubTimestamp":1760953463,"startTime":"0","endTime":"0","summary":"Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2575215930","title":"Chongqing Pharscin Pharmaceutical  Says Chairman and Shareholder Plan to Unload up to Combined 3% Stakes in Co Between November 6 and February 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2575215930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575215930?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:19","pubTimestamp":1760447944,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nL3N3VV18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2575215221","title":"BRIEF-Chongqing Pharscin Pharmaceutical's Chairman, Shareholder Plan To Unload Stakes","url":"https://stock-news.laohu8.com/highlight/detail?id=2575215221","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575215221?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:19","pubTimestamp":1760447944,"startTime":"0","endTime":"0","summary":"BRIEF-Chongqing Pharscin Pharmaceutical's Chairman, Shareholder Plan To Unload StakesOct 14  - Chongqing Pharscin Pharmaceutical Co Ltd 002907.SZ:SAYS CHAIRMAN AND SHAREHOLDER PLAN TO UNLOAD UP TO COMBINED 3% STAKES IN CO BETWEEN NOVEMBER 6 AND FEBRUARY 5, 2026Source textFurther company coverage: 002907.SZ  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nL3N3VV18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2570663340","title":"Chongqing Pharscin Pharmaceutical Gets China Municipal Drug Approval for Hepatitis, Blood Circulation Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2570663340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570663340?lang=en_us&edition=fundamental","pubTime":"2025-09-25 15:13","pubTimestamp":1758784437,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  obtained municipal drug approval for two products, according to a Thursday filing with the Shenzhen bourse.Authorities in Chongqing approved the reregistration for its diammonium glycyrrhizinate active pharmaceutical ingredient, which is extracted from licorice.The drug is indicated for acute and chronic viral hepatitis associated with high alanine aminotransferase levels, the drug company said.Officials also approved the reregistration of its sodium ferulate injection, which is used to enhance blood circulation in patients with ischemic cardiovascular and cerebrovascular disease, among other conditions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"1181952623","title":"Chongqing Pharscin Pharmaceutical (002907.SZ) Receives Drug Re-registration Approval Notices","url":"https://stock-news.laohu8.com/highlight/detail?id=1181952623","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181952623?lang=en_us&edition=fundamental","pubTime":"2025-09-24 16:14","pubTimestamp":1758701658,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that the company has recently received approval notices issued by the Chongqing Drug Administration regarding the \"Chemical Raw...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2566094161","title":"Pharscin Pharmaceutical Gets Extension for Two Drug Manufacturing Licenses1","url":"https://stock-news.laohu8.com/highlight/detail?id=2566094161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566094161?lang=en_us&edition=fundamental","pubTime":"2025-09-12 10:40","pubTimestamp":1757644800,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  obtained extensions for production authorization for esomeprazole sodium injection and vitamin D drops from the Chongqing regulator.The drug manufacturing licenses are now valid until November 2026 for esomeprazole sodium and June 2030 for vitamin D drops, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2565504272","title":"Pharscin Pharmaceutical Gets Nod to Become Authorized Marketer of Jian'er Xiaoshi Oral Liquid","url":"https://stock-news.laohu8.com/highlight/detail?id=2565504272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565504272?lang=en_us&edition=fundamental","pubTime":"2025-09-08 17:01","pubTimestamp":1757322072,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  obtained the approval of China's National Medical Products Administration become the marketing authorization holder of the Jian'er Xiaoshi oral liquid, according to a Shenzhen bourse filing on Saturday.The Chinese pharmaceutical company's shares rose over 2% at the close of Monday's trade.The drug is used to improve digestion.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2557367912","title":"Pharscin Pharmaceutical Pays 10 Million Yuan in Back Taxes, Late Fees","url":"https://stock-news.laohu8.com/highlight/detail?id=2557367912","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557367912?lang=en_us&edition=fundamental","pubTime":"2025-08-05 18:12","pubTimestamp":1754388731,"startTime":"0","endTime":"0","summary":"Chongqing Pharscin Pharmaceutical  paid 7.2 million yuan in enterprise income tax and 2.8 million yuan in late fees.The 10.0-million-yuan payment stemmed from discrepancies in the tax and accounting treatment of convertible bond interest expenses, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 6% lower Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2553012237","title":"Chongqing Pharscin Pharmaceutical Gets China Re-Registration Approval for Three Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2553012237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553012237?lang=en_us&edition=fundamental","pubTime":"2025-07-22 18:50","pubTimestamp":1753181446,"startTime":"0","endTime":"0","summary":"China granted Chongqing Pharscin Pharmaceutical  drug re-registration approval for three drugs, according to a Tuesday filing with the Shenzhen bourse.The Ganju Bingmei traditional Chinese tablets are indicated for pharyngitis and loss of voice, while its Liuwei Anshen traditional Chinese capsules are indicated for relief from phlegm and insomnia, the filing said.Meanwhile, its Cilostazol drug also obtained approval. The drug is indicated for anti-platelet aggregation and dilation of peripheral blood cells, among other effects, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","002907"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","stockEarnings":[{"period":"1week","weight":-0.0319},{"period":"1month","weight":0},{"period":"3month","weight":-0.103},{"period":"6month","weight":-0.124},{"period":"1year","weight":0.2315},{"period":"ytd","weight":0.023}],"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","perCapita":"9063股","boardName":"医药制造业","registeredCapital":"41759万元","compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0509},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.2696},{"period":"ytd","weight":0.0373}],"survey":"　　重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是耳鼻喉科用药、消化系统用药、精神神经系统用药、其他领域用药、医药商业、医药零售、其他业务。","serverTime":1769080404914,"listedPrice":4.53,"stockholders":"33091人(较上一季度增加0.84%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chongqing Pharscin Pharmaceutical Co.,Ltd.(002907),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chongqing Pharscin Pharmaceutical Co.,Ltd.(002907) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chongqing Pharscin Pharmaceutical Co.,Ltd.,002907,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票老虎,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票老虎国际,Chongqing Pharscin Pharmaceutical Co.,Ltd.行情,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票行情,Chongqing Pharscin Pharmaceutical Co.,Ltd.股价,Chongqing Pharscin Pharmaceutical Co.,Ltd.股市,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票价格,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票交易,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票购买,Chongqing Pharscin Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chongqing Pharscin Pharmaceutical Co.,Ltd.(002907),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chongqing Pharscin Pharmaceutical Co.,Ltd.(002907) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction